GMAB
Genmab A/S
NASDAQ · Healthcare · Biotechnology · DK
$33.60
−2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1B | 3.7B | 21.5B | 16.5B | 14.5B |
| Cost of Revenue | 288.0M | 309.2M | 985.0M | 226.0M | — |
| Gross Profit | 3.8B | 3.4B | 20.5B | 16.2B | 14.5B |
| Operating Expenses | |||||
| R&D Expense | 1.8B | 1.6B | 9.7B | 7.6B | 5.6B |
| SG&A Expense | 727.0M | 602.5M | 3.8B | 3.3B | 2.7B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 300.0M | — | — |
| Total Operating Expenses | 2.5B | 2.2B | 13.8B | 10.9B | 8.2B |
| Cost and Expenses | 2.8B | 2.5B | 14.8B | 11.2B | 8.2B |
| Operating Income (EBIT) | 1.3B | 1.3B | 6.7B | 5.3B | 6.3B |
| Non-Operating | |||||
| Interest Income | 129.9M | 138.1M | 995.0M | 939.0M | 324.0M |
| Interest Expense | 269.3M | 61.0M | 120.0M | 27.0M | 21.0M |
| Net Interest Income | (139.4M) | 77.1M | 875.0M | 912.0M | 303.0M |
| Other Non-Op Income/Expense | (428.0M) | (46.0M) | 2.5B | 316.0M | 678.0M |
| Non-Operating Income (excl Interest) | 158.7M | (15.0M) | (2.6B) | (386.0M) | (699.0M) |
| EBT (Pre-Tax Income) | 906.1M | 1.2B | 9.2B | 5.6B | 6.9B |
| Income Tax Expense | 118.0M | 241.2M | 1.3B | 1.3B | 1.5B |
| Bottom Line | |||||
| Net Income | 788.1M | 963.8M | 7.8B | 4.4B | 5.5B |
| Earnings from Cont. Ops | 788.1M | 963.8M | 7.8B | 4.4B | 5.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 788.1M | 963.8M | 7.8B | 4.4B | 5.5B |
| Per Share | |||||
| Basic EPS | $1.28 | $1.55 | $12.14 | $6.60 | $8.34 |
| Diluted EPS | $1.27 | $1.54 | $12.14 | $6.60 | $8.26 |
| Revenue Per Share | $6.74 | $5.99 | $33.30 | $24.99 | $22.18 |
| Shares | |||||
| Basic Shares Outstanding | 613.4M | 621.5M | 646.3M | 659.1M | 653.9M |
| Diluted Shares Outstanding | 617.1M | 626.9M | 646.3M | 659.1M | 660.1M |
| Profitability Metrics | |||||
| EBITDA | 1.2B | 1.3B | 9.7B | 5.9B | 7.3B |
| D&A | 44.0M | 71.1M | 413.0M | 240.0M | 362.0M |
| EBIT | 1.2B | 1.3B | 9.3B | 5.7B | 7.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026